Compare IDEXX Laboratories, Inc. (IDXX) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares Core MSCI EAFE ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares Core MSCI EAFE ETF trades at $96.52 (market cap $189.19B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 4.7× IDEXX Laboratories, Inc.'s market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares Core MSCI EAFE ETF for 40 Days on average.
| IDXX | IEFA | |
|---|---|---|
Market Cap | $40.43B | $189.19B |
Volume | 692,164 | 8,441,787 |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $101.41 |
52-Week Low | $504.70 | $85.06 |
Typical Hold Time | 46 Days | 40 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
IEFA, the iShares Core MSCI EAFE ETF, trades at $95.87, down 0.34% on the day, with a bearish technical signal driven by moving averages and oscillators. The fund provides exposure to developed markets outside North America, managing $196 billion in assets. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower costs relative to some peers, though it has underperformed others on a total return basis over the past year.
The outlook for IEFA is mixed, offering diversification benefits and income through dividends but facing headwinds from weaker relative performance and bearish technical momentum. Key risks include concentration in developed markets, which may lag during global growth shifts, and expense ratio competition. Analyst sentiment is cautious due to recent underperformance versus broader global funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
